AbbVie (ABBV) Revenue — Quarter Ended Sep 30, 2024
Revenue was essentially flat compared to the preceding quarter but edged higher than the same quarter a year ago. The trend reflects stable performance in the latest period.
Key takeaway
Quarter ended Sep 30, 2024 · FY2024 Q3
Revenue was essentially flat compared to the preceding quarter but edged higher than the same quarter a year ago. The trend reflects stable performance in the latest period.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$14.5B
Revenue reported for this quarter.
Quarter-over-quarter
-0.0%
Change from the immediately preceding quarter.
Year-over-year
+3.8%
Change from the comparable year-ago quarter.
Trailing four quarters
$55.5B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $14.3B | -5.4% |
| Mar 31, 2024 | $12.3B | +0.7% |
| Jun 30, 2024 | $14.5B | +4.3% |
| Sep 30, 2024 | $14.5B | +3.8% |
Revenue performance
Reported revenue showed no material change from the prior quarter, holding at the same level. Year-over-year, revenue edged higher, indicating modest growth from the same period twelve months earlier.
Quarterly comparison
Compared to the immediately preceding quarter, revenue was essentially unchanged. Versus the same quarter one year earlier, revenue was slightly higher.
What to watch
With revenue plateauing after prior sequential growth, future filings may clarify whether operating cash flow trends or acquisition-related costs affect topline direction.